Genmab
Clinical trials sponsored by Genmab, explained in plain language.
-
Promising melanoma combo trial halted early – only one patient enrolled
Disease control TerminatedThis study tested a new drug called acasunlimab, given alone or with pembrolizumab, in people with advanced melanoma that had stopped responding to standard treatments. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn about safet…
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody drug tested for tough blood cancers – but trial stopped early
Disease control TerminatedThis study tested a new experimental drug called GEN3014 (HexaBody-CD38) in people with multiple myeloma and other blood cancers that had returned or become resistant to treatment. The main goal was to check safety and find the right dose. The trial was terminated early, so the f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cancer drug GEN1057 tested in early trial – but study stopped early
Disease control TerminatedThis early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see how the drug behaves in the body. The study was terminated early, so results ar…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cancer drug trial halted early – what happened?
Disease control TerminatedThis study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug GEN1047 tested in humans – study halted early
Disease control TerminatedThis study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control TerminatedThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental combo therapy for advanced cancer shows early promise but trial cut short
Disease control TerminatedThis early-stage trial tested a new drug (GEN1042) combined with radiation, with or without another immunotherapy (pembrolizumab), in people with metastatic solid tumors that had no standard treatment options. The goal was to see if the combination was safe and could shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer drug GEN1078 tested in just 3 people – trial halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called GEN1078 in 3 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check for side effects and see how the body processes the drug. The trial was terminated early, so r…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody combo tackles solid tumors in early trial
Disease control TerminatedThis early-phase trial tested a new antibody drug, GEN1055, in 21 adults with advanced solid tumors. The goal was to check safety and find the right dose when used alone or with pembrolizumab (with or without chemotherapy). The study was stopped early, but results help guide futu…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New shot for tough lymphomas shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC